CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy

Ezgi Elmas¹,², Noushin Saljoughian²,³, Marcelo de Souza Fernandes Pereira², Brian P. Tullius⁴, Kinnari Sorathia², Robin J. Nakkula², Dean A. Lee²,⁵* and Meisam Naeimi Kararoudi²,³,⁵*

¹ Molecular, Cellular and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, United States, ² Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States, ³ CRISPR/Gene Editing Core, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States, ⁴ Pediatric Cellular Therapy, AdventHealth for Children, Orlando, FL, United States, ⁵ Department of Pediatrics, The Ohio State University, Columbus, OH, United States

Antitumor activity of immune cells such as T cells and NK cells has made them auspicious therapeutic regimens for adaptive cancer immunotherapy. Enhancing their cytotoxic effects against malignancies and overcoming their suppression in tumor microenvironment (TME) may improve their efficacy to treat cancers. Clustered, regularly interspaced short palindromic repeats (CRISPR) genome editing has become one of the most popular tools to enhance immune cell antitumor activity. In this review we highlight applications and practicability of CRISPR/Cas9 gene editing and engineering strategies for cancer immunotherapy. In addition, we have reviewed several approaches to study CRISPR off-target effects.

Keywords: NK cells, CRISPR, T cell, immunotherapy, off-target analysis, CRISPR screening, CAR-T cells, CAR-NK cell

INTRODUCTION

In recent years, adoptive T cell and NK cell therapies and immune checkpoint blockades have been successfully used in the clinic to improve immunotherapy for cancer. Immunotherapies with T and NK cells aim to overcome tumor-mediated immunosuppression and augment immunity against cancer (1–3). Adoptive T cell cancer immunotherapies comprehend tumor-infiltrating lymphocytes (TILs), transgenic T cell receptor (TCR)- T cell and chimeric antigen receptors (CAR)-T cell therapies (1). NK cell immunotherapies with cytokine stimulation, antibodies, and gene CAR-NK cells have been studied to overcome immunosuppression in cancers (2, 4). Although advancement in immunotherapy has been significant and durable, most cancer patients fail to respond to immunotherapy due to resistant tumor nature. Thus, we urgently need to find novel immunotherapies for cancer patients.

CRISPR/Cas9 gene-editing technology application has been widely studied and used in cancer immunotherapy research (5, 6). CRISPR method offers precise and powerful gene-editing efficiency in cancer and immunotherapy research. It has been used to identify essential genes as immune checkpoint targets, generate CAR-T and CAR-NK cells, construct TCR, understand signaling pathways, and screen for new druggable targets in immunotherapy (1, 7–10).
In this review, we describe the fundamentals of CRISPR gene editing in primary human T cells and NK cells. In addition, we highlight the applications of CRISPR/Cas9 technology in engineered T cells and NK cells and how it improves the immune cell function against cancers. Furthermore, several approaches to study off-target effects of CRISPR has been discussed.

**CRISPR GENE EDITING**

CRISPR are classes of repeated DNA sequences that act in coordination with CRISPR-associated (Cas) genes to devote bacterial and archaeal immunity against foreign raider phages and plasmid DNA (11). This system has been tested in several human cells including primary immune cells such as T-cells and NK cells. CRISPR consists of three elements: tracer-RNA, crispr-RNA (complementary to the target gene) and the Cas nuclease protein (12). Recognition of the target gene by guideRNA (Tracer-RNA + crispr-RNA) bound to Cas protein results in double stranded break (DSB) (5, 13, 14). DSBs can be repaired by one of the two highly conserved competing repair mechanisms, named as nonhomologous end-joining (NHEJ) or homology-directed repair (HDR) pathways (15). NHEJ results in insertion/deletion (indel) of nucleotides at the Cas9 targeting site and causes a frame shift in coding region and introduces gene knock-out (15). On the other hand, HDR is essential for insertion of a transgene such as a DNA template encoding a CAR into the Cas9 targeting site through homology repairs when homologous arms for the flanking region of Cas9 targeting site are provided in the DNA template (5). The best approach to deliver CRISPR elements and the DNA template depends on the target tissue or cell, packaging capacity, immunotoxicity, tropism, and integration site (5). Viral delivery has been widely used for human cells. Some of them are non-integrative, like the adeno-associated viruses (AAV) and adenoviruses (AdV), while some are integrative, such as Retroviridae family (MLV; murine leukemia virus or HIV; human immunodeficiency virus) (16, 17). Stable expression of the CRISPR in human primary cells is challenging due to the expression of anti-viral activity of the cells especially in NK cells and expressing a big protein like Cas9 results in low efficiency (18, 19). Therefore, delivery of pre-transcribed gRNA and pre-translated Cas9 as Cas9/ Ribonucleaseprotein (Cas9/RNP) has been favorable in immune cells (20, 21). Generation CAR expressing immune cells by site-directed gene insertion has been shown to be successful in both NK and T-cells. In this approach the DNA encoding a CAR is delivered as an HDR template by AAV vectors following electroperoration of Cas9/ RNP (22, 23). Providing optimal homology arms for Cas9-targeting site in the HDR template would be challenging as AAV has a small packaging capacity (less than 5 kb) (24). We have shown that a minimum of 300bp homology arms is required for high efficiency of the transgene integration into the Cas9 targeting site (23).

**INTRODUCTION TO T CELLS AND THEIR ROLE IN CANCER IMMUNOTHERAPY**

T cells are one of the most prominent components of the adaptive immune response. They can be distinguished from other lymphocytes by possessing TCR on their cell surface. T cells are developed in the thymus, and they recognize the antigen peptides presented by major histocompatibility complexes (MHC) class I and class II. T cells have two major CD8+ and CD4+ subtypes. CD8+ T cell refers to killer T cells, and CD4+ T cell refers to helper T cells. CD8+ killer T cells are involved in directly eradicating the virally infected cells as well as cancer cells. Even though T cells incredibly work and eliminate the most frustrating cancers, cancer remains one of the most devastating diseases globally and the leading cause of death. Conventional treatment options such as chemotherapy, radiotherapy and surgery have not been very effective in treating cancers. Recently, cell-based therapies, checkpoint blockades, cancer vaccines, oncolytic viruses and other forms of immunotherapies have shown promising clinical outcomes. T cell-based therapies are among the most efficient immunotherapies for cancer patients due to their eminent clinical efficacy (25). These new immunotherapies rely on the ability of T cells to eradicate tumors (26, 27). To enhance their antitumor activity and specificity, great interest in CAR- T cells has been evolved and have been used to treat hematologic malignancies and solid tumors. In autologous CAR-T cell-based therapies, the patient’s own T cells are genetically engineered to express a single-chain CAR which includes an antibody extracellular binding domain that recognizes a tumor cell surface antigen. Tumor antigen is recognized by extracellular domain of the CAR. Signaling activation is achieved by both costimulatory molecule such as CD27, CD28, 41BB and CD3zeta which contains ITAM motives (28). Thus, the engineered CAR-T cells can bind to tumor antigens and lyse the tumor cells independently from MHC, whereas normal T cells require TCR binding to an MHC class peptide antigen for their activation (19). Although CAR-T cell immunotherapies have been shown to be the most promising FDA approved cell based treatments, several challenges remain to be tackled (29). There has been some severe adverse events associated with CAR T cell toxicities (30–37). For example, most of the clinical trials use autologous T cells isolated from patients’ blood. This results in cell manufacturing failures from the early phase of the trial, due to low T cell quality and lymphocyte counts in some of the heavily treated patients (38). Manufacturing of autologous CAR T cell is a time-consuming process, therefore delaying the treatment in patients (33, 34). Additionally, when apheresis product is used for CAR-T cell production, sometimes failure in the process causes unsuccessful CAR-T cell manufacturing and poor response to treatment (30, 39–41). To overcome the problems related to autologous CAR-T cells, allogeneic CAR-T cell therapies has become alternative to autologous CAR-T cells (42–44). However, allogeneic CAR-T cell recognize and attack the recipient’s tissues causing graft-versus-host disease (GvHD) therefore limiting their use in the clinic (45–48). In addition to that, in both autologous and allogeneic CAR-T cells, side effects such as cytokine release syndrome (CRS) and neurologic toxicity in patients remains a challenge to overcome (34–37, 49–55). Efforts in gene-editing technologies such as CRISPR gene editing aid as a potential tool for overcoming the barriers in CAR-T immunotherapies (Figure 1) (27, 38, 56–62).
EXAMPLES OF CRISPR EDITED T CELLS

Genome editing technologies facilitate remarkable, highly efficient, and specifically targeted genomic modifications. CRISPR/Cas9 technology has been the most practical and efficient gene-editing method among other strategies for editing the T cells (63–66). Producing off-the-shelf universal CAR-T cells, overcoming T cell exhaustion, and suppressive TME become significant obstacles which CRISPR can be a suitable tool to tackle those issues (Figure 1) (44, 63). Several groups have reported successful gene editing of T-cells using Cas9/RNP (66, 67). Electroporation of Cas9/RNP to edit T-cells has been very efficient and been successfully used in the clinic to treat cancers (68). To solve the limitations of antigen-specific and HLA-matched T cells and generate universal allogeneic CAR-T cells, genetically engineered TCR complexes were developed for immune therapy. Targeted gene editing in T cells has major advantages over lentiviral transduction platforms. For example, lentiviral transduction of TCR leads to variable transgene copy numbers and untargeted transgene integration and therefore initiates variable TCR expression and functionality. Oppositely, TCR editing with CRISPR/Cas9 allows high-efficient gene targeting and avoids random integration (63, 64). CRISPR/Cas9 strategy has also been used to target PD-1, CTLA-4, LAG-3, and TIM-3 inhibitory molecules to overcome tumor mediated immune suppression and enhance CAR-T cell function (22, 69, 70). It also has been shown that diacylglycerol kinase (DGK) CRISPR-Cas9 KO improves the anti-tumor activity of CAR-T cells (71). TGF-β receptor II (TGFB2) KO with CRISPR/Cas9 was also shown to reduce CAR-T exhaustion and increase the anti-tumor activity of CAR-T cells (72). Inhibition of CD7 and TRAC using CRISPR/Cas9 enhances CAR-T cell-killing activity and prevents fratricide against T-ALL. Sterner et al. (73) showed that CRISPR/cas9 KO of granulocyte-macrophage colony-stimulating factor (GM-CSF) decreased the side effects like cytokine release syndrome and neuroinflammation of CAR-T cell therapies and also improved the CAR-T cell anti-tumor activity in-vivo (73). CRISPR/Cas9 gene not only used for KO, it has been also utilized for gene insertion of exogenous DNAs. Site directed gene knock-in (KI) has improved CAR-T cell antitumor efficiency (74, 75). Several approaches have been developed to deliver the DNA template encoding CARs. Schumann et al. introduced a HDR template into the CXC4 gene locus by electroporation of a plasmid DNA and Cas9/RNP, and demonstrated successful site directed KI (75). Moreover, insertion of CD19 specific CAR expressing DNA into the TRAC locus has been achieved with the CRISPR/Cas9 method and improved CAR-T cell efficiency. To generate these cells, T cells were electroporated with Cas9 mRNA and gRNA. Next, the HDR template encoding CD19 CAR was delivered to the cells via AAV6 transduction (60). In the T cell engineering era, insertions or deletions of short sequences with CRISPR/Cas9 technology have been very effective, precise, and routinely used. However, it has also been possible to KI longer sequences using ssDNA inserts called the Easi-CRISPR method with high efficiency (74). Cas9 is the most used endonuclease protein in CRISPR systems, but other Cas proteins such as Cas12 or Cpf1 is also used to generated CAR-T cells when combined with AAV gene delivery (22). To generate CAR-T cells with simultaneous KO of checkpoints and knock-in of double CARs, a method called KIKO has been developed. This method uses AAV-Cpf1 to generate KO and double knock-in KIKO-CAR-T cells (22, 76).

INTRODUCTION TO NK CELLS

Natural Killer Cells (NK cells) are type of innate lymphocytes mediates anti-viral and anti-tumor activity. NK cells develop in

---

**FIGURE 1** | CRISPR gene editing in T-cells. Several gene KO and KI have been tested in T-cells, here we summarized the targeted genes. T cell checkpoint inhibitory receptor KO such as TIM3, CTLA-4 and PD-1 KO resulted in higher antitumor activity of T-cells. CAR-T cell signaling modulation via inhibition of immunosuppressive TGF-β signaling showed significant improvement of CAR-T cells. Integration of CAR-T in TRAC locus may solve the mentioned problems with allogeneic CAR-T therapies.
the bone marrow (BM) and secondary lymphoid tissues such as, tonsils, spleen and lymph nodes (LNs) and they represent 5-20% of circulating lymphocytes in humans (77, 78). NK cells are distinguished from the other immune cells by possessing CD3+ and CD56+ phenotype. Human NK cell subsets express also CD16 molecule, which is involved in antibody dependent cellular cytotoxicity (ADCC). NK cells are effector cytotoxic cells, they recognize and destroy their target without prior sensitization. Unlike T cells, they do not need MHC class presentation to enact their cytotoxic properties. Unlike T cells, NK cells recognize and kill tumor in an HLA-independent manner which result in being known as a great candidate for allogeneic anti-tumor cell-based therapies, as they do not cause acute GvHD (79–81). NK cells use KIR receptor and ligand mismatch to recognize cancer cells from self-cells, therefore mediating enhanced engraftment, anti-tumor response, and safe clinical outcomes (79, 81–85). NK cell killing of target cells accomplished with a balance of activating and inhibitory signals engaged around the cell. NK cell activating receptors includes, killer cell’s immunoglobulin-like receptors (KIRs), KIR2DS2, KIR2DS5, KIR3DS1, CD94/NKG2C, NKG2D, Nkp30, Nkp40, Nkp44 and Nkp46 recognize ligands present on target cells. NK cells have the ability of recognize non-self by Nkp80, SLAM, CD18, CD2 and TLR3/9 receptors. Some of the NK cell inhibitory ligands are PD-1, TIGIT, TIM-3 and LAG-3. Inhibitory KIR ligands, KIR2DL1, 2DL2, and 2DL3 interact with highly polymorphic human leukocyte antigen (HLA). There are three HLA groups, group 1, 2 and HLA-Bw4, which usually bind inhibitory KIR and have long extracellular immunoglobulin structure. It has been shown that patients who receive NK cell immunotherapy containing haplo-mismatched NK cells they have anti-leukemic effects without the risk of GVHD. In hematopoietic stem cell transplant (HSCT) patients, infusions of haplo-mismatched KIR and HLA NK cells has shown benefits of survival and lower relapse rates. If the infused NK cells are identical, they show benefit if the KIR receptors are activating (86, 87). NK cells can be isolated from peripheral blood, umbilical cord, and induced pluripotent stem cells (iPSCs) (88–91). Once isolated from their primary source, feeder cells, such membrane-bound IL-21 K562s, used to expand NK cells ex-vivo (92). They can be cultured anywhere from 14-21 days in most protocols and can proliferate remarkably over hundreds of folds (92). Cytokines such as IL-2, IL-12, IL-15, IL-18, and IL-21 are also added in NK cell cultures to enhance NK cell proliferation and activation (86, 87). NK cells have several mechanisms to eradicate their targets. One of the main mechanisms is perforin and granzyme induced apoptosis. Granzymes which are serine/proteases, packaged along with perforin and when they release by NK cells, they initiate target apoptosis via caspase-3 pathway. In addition to that, NK cells via Fas ligand and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) pathways can destroy their targets (93–95).

EXAMPLES OF CRISPR MODIFIED NK CELLS

CRISPR editing of NK cells has been challenging, however we and others have shown that using electroporation of Cas9/RNP can solve the issue of low viral transduction efficiency of NK cells (18, 23, 96–103). Gene editing in NK cells in a short period since its invention has been used for serval applications such as to improve their metabolic function, knocking-out checkpoint molecules, improving antibody therapies and generation of CAR-NK (96). One great example of gene engineered NK cells is CD38 knock-out NK cells. NK cells highly express CD38 on their surface. Patients treated with daratumumab (Dara, hereafter), a monoclonal antibody targeting CD38 on multiple myeloma, showed a decrease in NK cells number. This is a result of NK-NK recognition through CD16 binding to Dara coated CD38+ NK cells, referred to as “fratricide.” Beyond the role of the structural marker, CD38 is well described to be associated with a large diversity of physiological and pathological conditions. Our group and others successfully developed NK cells lacking CD38 by introducing the CRISPR/Cas9 as Cas9/ RNP via electroporation (96, 101). In particular, CD38 is an NAD-degradation enzyme in mammalian tissues (104–110). Our data demonstrated that CD38KO NK cells have more prominent metabolic profile, increased killing mediated by ADCC against CD38+ multiple myeloma cell lines and patient derived samples and are protected from fratricide mediated by daratumumab (96, 101).

Another important target to improve the NK cell’s function is CHS encoded by CIS gene. CISH has a critical impact on NK cells, and its activation is known to disable JAK-STAT downstream signaling pathways including a decline in NK cell ability to kill malignant cells (111, 112). Different groups have shown that CISH is overexpressed in the presence of IL-2 and IL-15 (113–115). IL15 was previously described as an important factor potentiating NK cells cytokine production and cytotoxicity activity (116–118). Felices et al. have demonstrated that prolonged administration of IL15 can unleash NK cells exhaustion via metabolic failure (119). Delconte et al. showed that CISH was quickly activated after IL15 stimulation in a mouse model, supporting that using gene-editing in NK cells to delete CISH seems to be advantageous (120). Using CRISPR/ Cas9 on human iPSC to generate iPSC-CISH knockout NK cells displayed prolonged persistence in vivo and enhanced antitumor activity for acute myeloid leukemia (121, 122). NK cell checkpoint blockade has been used as a promising therapy for liquid and solid tumors. Other candidate for gene editing in NK cells is NKG2A which is an immune checkpoint in CD8+ T cells, natural killer T cells (NKT) and CD56hi NK cells. Upon activation of immune cells, NKG2A leads to decreased effector function (123, 124). Data from the literature have shown that NKG2A drives NK cells to fatigue when highly expressed, and it can be predictive of poor prognosis in liver cancer patients (125). Thus, the blockade of the NKG2A receptor enhances NK cell’s effector function for immunotherapy (126–128). Similarly, Berrien-Elliott et al., have shown that gene-editing using CRISPR/CAS9 to delete NKG2A from human NK cells was able to increase NK cell ability to control HLA-E0 K562 leukemia when compared to control NK cells demonstrating a substantial inhibitory function for NKG2A (129). Additionally, NKG2A0 KO NK cells did not affect their persistence in NSG mouse model.
(129), however, the role of NKG2A in NK cells licensing may cause development of unlicensed NK cells with lower cytotoxic activity (130). It is very well established that the PD1/PD-L1 axis has an inhibitory function that can impair many T cells' functions. This fact has been validated in preclinical models where the inhibition of this signaling cascade is used for cancer treatment (131). Indeed, high expression of PD1 ligand I or II in tumor cells, immune cells, including T cells and NK cells are present in tumors rejection in the murine model (132, 133). The blockage of the PD1/PD-L1 axis with monoclonal antibodies repair these effects and unleash T cells to effectively kill tumor cells (132–134). Recently it has been shown that in different malignancies, human NK cells also express PD-1 (135–139). Like T cells, blockade of the PD1/PD-L1 axis was able to activate NK response (140). However, such strategies present limitations, especially regarding off-target toxicity (102). Pomeroy et al. could generate PD1 KO NK cells by electroporating mRNA repair these effects and unleash T cells to effectively kill tumor cells (140). Therefore, the use of CRISPR/Cas9 to target PD1 in NK cells is an intriguing opportunity (98). However, this strategy presents some limitations, especially regarding off-target toxicity (102). Pomeroy et al. could generate PD1KO NK cells by electroporating mRNA Cas9 and gRNA (102). They demonstrated that PD1KO NK cells showed notably enhanced cytotoxicity and cytokine secretion in vitro and in vivo, decreasing tumor burden that culminated with survival (102). Another promising target for gene editing to boost cancer immunotherapy is the Suppressor of cytokine signaling 3 (SOCS3). The protein SOCS3 is one among eight members of the Suppressor of cytokine signaling family (SOCS1–7 and CIS). Those proteins downregulate cytokine signaling via the JAK/STAT signaling cascade. Murine NK cells upregulated SOCS3 expression after IL-15 stimulation (120). SOCS3 impairs NK cells function upon IL15 stimulation (120). SOCS3 impairs the in vitro and in vivo outcome of the NK cells therapy (151). Overall, gene editing of NK cells has been challenging but the recent successes in using CRISPR by electroporating Cas9/RNP helped to improve the outcome of the NK cells therapy (Figure 2) (18, 101, 103, 152, 153). There has been some evidence showing that Polymer-stabilized Cas9 nanoparticles and modified repair templates can improve genome editing efficiency. These modified nanoparticles improved knock-out and knock-in efficiency of the CRISPR gene editing in several primary cells such as NK and T cells (16).
OFF-TARGET ANALYSIS OF CRISPR EDITED IMMUNE CELLS

Recently by the promises of Cas9 endonuclease, researchers can target multiple genes in immune cells, including T cells and Natural killer (NK), to improve cancer immunotherapy. For these applications that lead to clinical cancer immunotherapy, the induced mutations by CRISPR-Cas9 should be highly precise and specific for the targeted loci with high on-target efficiency and low or no off-target activity. However, rare off-target events are inescapable during the manipulation of the gene of interest. This phenomenon requires scrutiny identification, especially in clinical applications to cure cancers and avoid adverse effects during cancer immunotherapy such as introduction of an oncogene. By developing next-generation sequencing (NGS) a survey of new functional and non-functional variations during gene manipulation became possible (154, 155). NGS has been broadly applied by researchers and employed in clinical trials due to its development in data acquisition with speedy and high-quality recognition (156, 157). Analyzing these NGS-generated data is even more critical to optimize and manage the workflow to fill the gap between massive data and scientific exploration. To date, several methods have been invented to analyze NGS data and off-target effects of CRISPR mediated mutations, such as GUIDE-seq, SITE-Seq, CHANGE-seq, Cas-OFFinder and Churchill (158–162). Some of them like GUIDE-seq, SITE-Seq and CHANGE-seq are based on the PCR amplification of pre-selected potential sites, which predicted by CRISPR/Cas9 design tools, and sequencing the PCR amplicons utilizing Sanger or NGS technologies (158–160, 163). For instance, Schumann et al.,

TABLE 1 | Examples of clinical trials with CRISPR/Cas9 gene edited T cells (151).

| National Clinical Trial Number | Cancer | CRISPR target gene | T cell source | Technique | Country |
|-------------------------------|--------|---------------------|---------------|-----------|---------|
| NCT04037566                  | Relapsed or refractory ALL and B-cell lymphoma | HPK1              | Autologous T cells | Rnp Electroporation | China    |
| NCT03999448                  | Multiple myeloma, melanoma, synovial sarcoma, myoid/round cell liposarcoma | TCRα, TCRβ and PD-1 | Autologous T cells | Rnp Electroporation | USA      |
| NCT03545815                  | Solid tumors | Endogenous TCR and PD-1 | T cells (unknown source) | N/A | China    |
| NCT04244656                  | Refractory multiple myeloma | B2M gene and TCR | Allogeneic T cells | N/A | USA and Australia |
| NCT03747965                  | Solid tumors | PD-1              | T cells (unknown source) | N/A | China    |
| NCT04035434                  | B-cell malignancies | B2M gene and TCR | Allogeneic T cells | N/A | USA and Australia |
| NCT03166878                  | B-cell leukemia and lymphoma | B2M gene and TCR | Allogeneic T cells | Rnp Electroporation | China    |
| NCT03404743                  | EBV related diseases | PD-1              | EBV CTL from autologous source | N/A | China    |

N/A stands for non-applicable.

FIGURE 2 | CRISPR gene editing in NK cells. Several gene KO in NK cells have been done to improve NK cell function; here, we show some of the NK cell gene modifications. CD38 and SOCS/CISH KO can improve metabolism in NK cells. Inhibitory checkpoint receptor KO such as NKG2A and PD-1 KO. ADAM17 KO enhance CD16 mediated ADCC. Anti-CD19 CAR NK cells increase IL-15 production and enhance NK cell anti-tumor activity.
used a 2-step PCR method and sequenced with the amplicons with Illumina HiSeq, and identified indel mutations and their spatiality distribution in the target region in primary human T cells (75). In another study the efficiency and indel rates in the created CAR-T cells, using CRISPR-Cas9-mediated multiplex gene editing, was quantified by both single-cell assay and tracking of indels by decomposition (TIDE) analysis (58). Stadtmauer et al. utilized iGUIDE, a modified method of GUIDE-seq, for the Cas9-mediated cleavage specificity analysis in the engineered T cells to cure refractory cancer and found no clinical toxicities (68, 158, 164). Although these methods are simple and available to most molecular biology laboratories, they are not always precise as they are based on the predictions of potential off-target sites by CRISPR/Cas9 design tools in the genome of interest and therefore result in studying limited loci. As a matter of fact, DSBs happened beyond the predicted sites and may be ignored and caused detrimental side effects during the process of clinical cancer immunotherapy (163). This major disadvantage of off-target mutations identification by PCR based methods have been resolved by whole genome sequencing (WGS) which is unbiased and has been used to screen for off-target mutations induced by CRISPR/Cas9 in different cells including human inducible pluripotent stem cells, primary T cells, CAR-T cells (163, 165–167). Using this method, researchers can recognize both small indels and SNPs as well as major deletions, inversions, duplications and, rearrangements (163, 166). The only restriction of whole genome sequencing is missing the most low-frequent off-targets that happens to a small number of clones (163, 168). Cas-OFFinder algorithm have been invented in order to search for potential off-target sites in any sequenced genome regions (161). In a clinical trial, the safety and feasibility of CRISPR–Cas9 PD-1-edited T cells were confirmed after analyzing all the potential off-targets using Cas-OFFinder method in the treatment of lung cancer (169). More recently, as an ultra-fast, definite, highly scalable, and balanced parallelization strategy for discovering human genetic variation in clinical and population-scale genomics, Churchill has been applied for the analysis of next-generation sequencing data (162).

We reported the high efficacy of Churchill analysis in verifying off-target events after deletion of CD38 in NK cells via Cas9/RNP and showed low off-target effects of Cas9/RNP (96). It has successfully revealed all the existing mutations and categorized them as missense and non-frameshift and moderate or high impact (96). Overall, WGS can provide more precise landscape of the off-target effects in CRISPR-edited cells. Here, we summarize and compare the current methods in off-target effects analyses of CRIPR edited immune cells (Table 2).

### CRISPR Screening in Primary Immune Cells

Genome wide CRISPR screen has been used in several cancer cells to discover novel targets for cancer immunotherapy. CRISPR screening approach has not been extensively used in human primary immune cells due to several technical challenges. However, some studies have shown successful screening approaches in human primary T cells and Cas9-expressing transgenic mice in recent years (19, 170–172). In general, to perform a CRISPR screen we need to introduce Cas9 and gRNA pool library into the cells (173). These molecules usually delivered to the target cells via lentiviral transduction. However, expressing large proteins such as cas9 using LV vectors in immune cells such as NK cells and T-cells has been challenging and results in low transduction efficiency. Shifrut

| Off target analysis method | Definition | Pros | Cons |
|---------------------------|------------|------|------|
| Cas-OFFinder (161) | It is an algorithm that searches for possible off-target sites that can be found in an already sequenced genome. | - It is not limited by the number of mismatches and the PAM sequence.  
- It allows alterations in PAM sequences which are differentiable with Cas9.  
- a rapid and highly assorted off-target searching tool available at http://www.rgenome.net/cas-offinder | - It relies on a computational method, which may result in ignoring some potential off-targets sites.  
- it is biased due to the assumption that off-target sequences are affiliated with the on-target site which may cause missing off-target sites in any loci throughout the genome.  
- DNA-repair machinery does not have a role in the process as it is performed on high molecular weight DNA. |
| SITE-Seq (selective enrichment and identification of tagged genomic DNA ends by sequencing) (169) | It is a biochemical method, using Cas9 and single-guide RNAs (sgRNAs), to recognize all the Cas9-mediated cut site sequences inside the genomic DNA. | - It allows retrieval of off-target sites with different cleavage sensitivity by utilizing a vast range of sgRNPs concentrations from very low to high.  
- Provides guidance for precise and plenary inspection of possible off-target sites in cells by gaging the incidence of mutations and their functional cellular effects.  
- Production of sequencing libraries which are highly enriched for | |

(Continued)
et al.; tested a hybrid approach in which the Cas9 was introduced to the gRNA library expressing cells via electroporation (19). They developed Single guide RNA (sgRNA) lentiviral infection with Cas9 protein electroporation (SLICE) and resulted in discovery of novel genes important in activation and expansion of CD8 T-cells (19). A similar approach was used by other groups to perform CRISPR screening in CAR-T cells (174). To date, there is no publication on CRISPR-screening on NK cells. Our

**TABLE 2 | Continued**

| Off target analysis method | Definition | Pros | Cons |
|---------------------------|------------|------|------|
| GUIDE-seq (genome-wide, unbiased identification of DSBs enabled by sequencing) (158) | It is a PCR-based method that relies on the enteral of double-stranded oligodeoxynucleotides into the DSB caused by RNA-guided nucleases (RGN) without contributing to off-target site. | sgRNA cut sites, providing unique profiling with minimal read depth. | - Relies on an integration of donor sequences, which usually happens in a low frequency. - mispriming may occur due to the annealing of PCR primers to DNA sequences apart from the ODN, resulting in PCR products that are not differentiable from products formed by primers binding to the ODN. |
| iGUIDE (improvement of the GUIDE-seq method) (164) | GUIDE-seq method allows mis priming artifacts to be recognizable from credible ODN integration sites by using a larger ODN (46 nt versus 34 nt). | by using larger ODN, PCR primer binding sites can be back off from the junction of the ODN in the final PCR product and can cause mis priming events. | - Relies on an integration of donor sequences, which usually happens in a low frequency. - mispriming may occur due to the annealing of PCR primers to DNA sequences apart from the ODN, resulting in PCR products that are not differentiable from products formed by primers binding to the ODN. |
| ChIP-seq (chromatin immunoprecipitation sequencing) (158) | It identifies the off-target binding sites by using catalytically dead Cas9 (dCas9)-gRNAs complex. | Important for the identification of the genome-wide binding sites with dCas9 fusion proteins. | - It rarely indicates the off-target sites of cleavage caused by active Cas9 nuclease. - not effective for recognition of genome-wide, off-target cleavage sites for catalytically active RGNs. |
| CHANGE-seq (circularization for high-throughput analysis of nuclease genome-wide effects by sequencing) (160) | It is a high-throughput procedure for determining the genome-wide operations of CRISPR-Cas9 nucleases based on Tn5 mediated gDNA tagmentation in vitro. | A simplified, susceptible, and scalable approach. - It can elucidate the genome-wide perspective of genome editing activity exquisitely sensitive. | - It relies on the Tn5 tagmentation of donor sequences. - Similar to SITE-Seq, the DNA repair machinery is ignored. |
| Churchill (162) | In clinical and population-scale genomics provides fast, decisive, scalable, and balanced parallelization tactic for the detection of human genetic mutation. | It uses a robust comparison based on whole genome sequencing data comparing wildtype and CRISPR edited cells. | - Limited access to the platform and the algorithm is not publicly available yet. |

---

Churchill (162) In clinical and population-scale genomics provides fast, decisive, scalable, and balanced parallelization tactic for the detection of human genetic mutation.
group is investigating some new approaches to overcome issues related to lentiviral transduction of NK cells.

CONCLUSION

CRISPR gene editing technology has shown to be a very versatile tool for improving anti-tumor activity of NK cells and T-cells. We reviewed here some of the CRISPR edited cells used for cancer immunotherapy. We also reviewed ways to determine the off-target effects of CRISPR and emphasized that Cas9/RNP approach results in low off-target effects. We also mentioned how important information can be discovered by CRISPR screening approach and there are a lot to do the efficiently optimize this method to be used in NK cells and T cells. Overall, CRISPR gene editing shows promising clinical outcome and have potentials to be used more broadly Clinical applications such as cancer immunotherapy using NK cells and T cells.

AUTHOR CONTRIBUTIONS

The corresponding authors MNK and DAL supervised the authors for manuscript completion. The first author EE contributed to manuscript writing and revising. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Ou X, Ma Q, Yin W, Ma X, He Z. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More. Front Cell Dev Biol (2021) 9:674467. doi: 10.3389/fcell.2021.674467
2. Afsharin LO, Aleshkin AO, Sani MM, Bi JW, Wan X. Genetic Reprogramming for NK Cell Cancer Immunotherapy With CRISPR/Cas9. Immunology (2019) 158:63–9. doi: 10.1111/imm.13904
3. O’Donnell JL, Teng MWL, Smyth MJ. Cancer Immunoediting and Resistance to T Cell-Based Immunotherapy. Nat Rev Clin Oncol (2019) 16:151–67. doi: 10.1038/s41571-018-0142-8
4. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK Cell-Based Immunotherapy for Malignant Diseases. Cell Mol Immunol (2013) 10:2320–52. doi: 10.1038/cmi.2013.10
5. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science (2013) 339:819–23. doi: 10.1126/science.1231143
6. Platt RJ, Chen S, Zhou Y, Yin MJ, Swiech L, Kemperton HR, et al. CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling. Cell (2014) 159:440–55. doi: 10.1016/j.cell.2014.09.014
7. Evers B, Jastrzębski K, Heijmans JP, Greerann W, Beijersbergen RL, Bernards R. CRISPR Knockout Screening Outperforms shRNA and CRISPRi in Identifying Essential Genes. Nat Biotechnol (2016) 34:631–3. doi: 10.1038/nbt.3356
8. Tzalepis K, Koike-Yusa H, De Braekeleer M, Li Y, Metzakopian E, Dovey OM, et al. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Rep (2016) 17:1193–205. doi: 10.1016/j.celrep.2016.07.097
9. Pettitt SJ, Krastev BD, Brandsmia I, Dreán A, Song F, Aleksandrova R, et al. Genome-Wide and High-Density CRISPR-Cas9 Screens Identify Point Mutations in PARP1 Causing PARP Inhibitor Resistance. Nat Commun (2018) 9:1849. doi: 10.1038/s41467-018-03917-2
10. Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, et al. Genome-Wide CRISPR/Cas9 Library Screening Identified PHGDH as a Critical Driver for Sorafenib Resistance in HCC. Nat Commun (2019) 10:6841. doi: 10.1038/s41467-019-12456-7
11. Wiedenheft B, Sternberg SH, Doudna JA. RNA-Guided Genetic Silencing Systems in Bacteria and Archaea. Nature (2012) 482:331–8. doi: 10.1038/nature10886
12. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science (2012) 337:816–21. doi: 10.1126/science.1225829
13. Cemmensen OJ, Moll M, Arpi M, de Fine Olivarius N, Nielsen JR. [Bacteriological Autopsy. The Value of Postmortem Heart Blood Culture]. Ugeskr Laeger (1988) 150:101–3.
14. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-Programmed Genome Editing in Human Cells. Elife (2013) 2:e00471. doi: 10.7554/eLife.00471
15. Kass EM, Jasin M. Collaboration and Competition Between DNA Double-Strand Break Repair Pathways. FEBS Lett (2010) 584:3703–8. doi: 10.1016/j.febslet.2010.07.057
16. Nguyen DN, Roth TL, Li PJ, Chen PA, Apothy R, Mamedov MR, et al. Polymer-Stabilized Cas9 Nanoparticles and Modified Repair Templates Increase Genome Editing Efficiency. Nat Biotechnol (2020) 38:34–9. doi: 10.1038/s41552-019-0325-6
17. Verheyen E. Advances in Foamy Virus Vector Technology and Disease Correction Could Speed the Path to Clinical Application. Mol Ther (2012) 20:1105–7. doi: 10.1038/mt.2012.97
18. Najimi Kararoudi M, Tullius BP, Chakravarti N, Pomeroy EJ, Moriarity BS, Beland K, et al. Genetic and Epigenetic Modification of Human Primary NK Cells for Enhanced Antitumor Activity. Semin Hematol (2020) 57:201–12. doi: 10.1055/s.0031-1303961
19. Shifrut E, Carnevale J, Tobin V, Roth TL, Woo JM, Bui CT, et al. Genome-Wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. Cell (2018) 175:1958–71.e15. doi: 10.1016/j.cell.2018.10.024
20. Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced Homology-Directed Human Genome Engineering by Controlled Timing of CRISPR/Cas9 Delivery. Elife (2014) 3:e04766. doi: 10.7554/eLife.04766.010
21. Najimi Kararoudi M, Dolatshah H, Trikha P, Hussain SA, Elmas E, Foltz JA, et al. Generation of Knock-Out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Virol (2018). doi: 10.1128/jvi.02356-17
22. Dai X, Park JJ, Du Y, Kim HR, Wang G, Errami Y, et al. One-Step Generation of Modular CAR-T Cells With AAV-Cpf1. Nat Methods (2019) 16:247–54. doi: 10.1038/s41397-019-0329-7
23. Kararoudi MN, Lkhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, et al. CRISPR-Targeted CAR Gene Insertion Using Cas9/RNP and AAV6 Enhances Anti-AML Activity of Primary NK Cells. bioRxiv (2021). 2021.03.17.435886. doi: 10.1101/2021.03.17.435886
24. Dong JY, Fan PD, Frizzell RA. Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus. Hum Gene Ther (1996) 7:2101–12. doi: 10.1089/hum.1996.7.17-2101
25. Zhi L, Su X, Yin M, Zhang Z, Lu H, Niu Z, et al. Genetic Engineering for NK and T Cell Immunotherapy With CRISPR/Cas9 Technology: Implications and Challenges. Cell Immunol (2021) 369:104436. doi: 10.1016/j.cellimm.2021.104436
26. Taniuchi I, CD4 Helper and CD8 Cytotoxic T Cell Differentiation. Annu Rev Immunol (2018) 36:579–601. doi: 10.1146/annurev-immunol-042617-053411
27. Guedan S, Ruella M, June CH. Emerging Cellular Therapies for Cancer. Annu Rev Immunol (2019) 37:145–71. doi: 10.1146/annurev-immunol-042718-041407
28. Terry RL, Meyran D, Fleuren EGD, Mayoh C, Zhu J, Omer N, et al. Chimeric Antigen Receptor T Cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. Cancers (2021) 13:4704. doi: 10.3390/cancers13184704
29. Pavlovic K, Tristán-Manzano M, Maldonado-Pérez N, Cortijo-Gutierrez M, Sánchez-Hernández S, Justicia-Lirio P, et al. Using Gene Editing Approaches
CRISPR Modified NK and T Cells

30. Rafaj S, Hackett GS, Brentjens RJ. Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy. Nat Rev Clin Oncol (2020) 17:147–67. doi: 10.1038/s41571-019-0297-y

31. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric Antigen Receptor T-Cell Therapy - Assessment and Management of Toxicities. Nat Rev Clin Oncol (2018) 15:47–62. doi: 10.1038/nrclinonc.2017.148

32. Park JH, Rivière I, Gonen M, Wang X, Seiler M, et al. Off-The-Shelf CRISPR/Cas9-Mediated Multiplex Gene Editing in CAR-T Cells. Blood Adv (2017) 1:262–76. doi: 10.1182/bloodadvances.2018013704

33. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Chimeric Antigen Receptor T-Cell Therapy - The Diametric Opposition of T Cells. J Clin Invest (2016) 126:2123–38. doi: 10.1172/JCI85309

34. Liu X, Zhang Y, Cheng C, Cheng AW, Zhang X, Li N, et al. CRISPR-Cas9-Mediated Multiplex Gene Editing in CAR-T Cells. Cell Res (2017) 27:154–7. doi: 10.1038/cr.2016.142

35. Georgiadi C, Preece R, Nickolay L, Etuk A, Petrova A, Ladon D, et al. Long-Term Repeat CAR-CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-Leukemic Effects. Mol Ther (2018) 26:1251–7. doi: 10.1038/mt.2018.02.25

36. Eyquem J, Marsilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, et al. CRISPR/Cas9-Mediated Gene Knockout in Primary T Cells. Sci Rep (2017) 7:303ra139. doi: 10.1038/s41598-018-00346-9

37. Johnson LA, June CH. Driving Gene-Engineered T Cell Immunotherapy of Cancer. Br J Haematol (2019) 184:257–71. doi: 10.1111/bjh.15744

38. Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia. Sci Transl Med (2015) 7:303ra139–303ra139. doi: 10.1126/scitranslmed.aac5415

39. Rupp LJ, Smith CM, De Cabbalini V, Ruchelli E, Lamprecht M, et al. CRISPR-Cas9-Mediated Gene Knockouts Inhibit T Cell Function. Blood Adv (2017) 1:4254–64. doi: 10.1182/bloodadvances.2016013275

40. Omori K, Nagata N, Kurata K, Fukushima Y, Sekihachi E, Fujii N, et al. Inhibition of Stromal Cell-Derived Factor-1alpha/CXCR4 Signaling Restores T-Cell Function in Chronic Leukemia. Cancer Med (2018) 7:1227–37. doi: 10.1002/cam4.2257

41. Soteriades J, Hemon M, Brudno JN, Portier J, et al. Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management. Blood Rev (2019) 34:45–55. doi: 10.1016/j.bleu.2018.11.002

42. Park JH, Rivière I, Gonen M, Wang X, Seiler M, et al. Off-The-Shelf CRISPR/Cas9-Mediated Multiplex Gene Editing in CAR-T Cells. Blood Adv (2017) 1:262–76. doi: 10.1182/bloodadvances.2018013704

43. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, et al. Allogeneic and Autologous CAR-T-Cell Therapy to Treat an Immune-Compromised Leukemic Patient. Blood Adv (2018) 2:1691–5. doi: 10.1182/bloodadvances.2018037084

44. Sanber K, Savani B, Jain T. Graft- Versus-Host Disease Risk After Chimeric Antigen Receptor T-Cell Therapy: The Diametric Opposition of T Cells. Br J Haematol (2021) 195:660–8. doi: 10.1111/bjh.17544

45. Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia. Sci Transl Med (2015) 7:303ra139–303ra139. doi: 10.1126/scitranslmed.aac5415

46. Rupp LJ, Smith CM, De Cabbalini V, Ruchelli E, Lamprecht M, et al. CRISPR-Cas9-Mediated Gene Knockouts Inhibit T Cell Function. Blood Adv (2017) 1:4254–64. doi: 10.1182/bloodadvances.2016013275

47. Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, et al. CRISPR/Cas9-Mediated PD-1 Disruption Enhances Human Mesothelin-Targeted CAR T Cell Effector
Functions. Cancer Immunol Immunother (2019) 68:365–77. doi: 10.1007/s00262-018-2281-2

68. Stadler EA, Frazzetta IA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-Engineered T Cells in Patients With Refractory Cancer. Science (2020) 367:eaba7365. doi: 10.1126/science.aba7365

69. Muller TR, Jarosch S, Hammel M, Leube J, Grassmann S, Bernard B, et al. Targeted T Cell Receptor Gene Editing Provides Predictable and Predictable T Cell Product Function for Immunotherapy. Cell Rep Med (2021) 2:e100374. doi: 10.1016/j.xcrm.2021.100374

70. Morimoto T, Nakazawa T, Matsuda R, Nishimura F, Nakamura M, Yamada S, et al. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Giemsa Cells. Int J Mol Sci (2021) 22. doi: 10.3390/ijms22073410

71. Jung IY, Kim YY, Yu HS, Lee M, Kim S, Lee J. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. Cancer Res (2018) 78:4692–703. doi: 10.1158/0008-5472.CAN-18-0030

72. Tang N, Cheng C, Zhang X, Qiao M, Li N, Wu M, et al. TGF-Beta Inhibition via CRISPR Promotes the Long-Term Efficacy of CAR T Cells Against Solid Tumors. JCI Insight (2020) S. doi: 10.1172/jci.insight.133977

73. Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. GM-CSF Inhibition Reduces Cytokine Release Syndrome and Neuroinflammation But Enhances CAR-T Cell Function in Xenografts. Blood (2019) 133:697–709. doi: 10.1182/blood-2018-10-881722

74. Miura H, Quadros RM, Gurnamurthy CB, Ohtsuka M. Easi-CRISPR for Creating Knock-in and Conditional Knockout Mouse Models Using Long ssDNA Donors. Nat Protoc (2018) 13:195–215. doi: 10.1038/nprot.2017.153

75. Schumann K, Lin S, Boyer E, Subramaniam M, Gate RE, et al. Generation of Knock-in Primary Human T Cells Using Cas9 Ribonucleoproteins. Proc Natl Acad Sci USA (2015) 112:10437–42. doi: 10.1073/pnas.1512503112

76. Zhang X, Cheng C, Sun W, Wang H. Engineering T Cells Using CRISPR/ Cas9 for Cancer Therapy. In: Mi Soid, editor. RNA Interference and CRISPR Technologies: Technical Advances and New Therapeutic Opportunities. New York, NY: Springer US (2020). p. 419–431

77. Abl AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol (2018) 9. doi: 10.3389/fimmu.2018.01869

78. Scoville SD, Freud AG, Caligiuri MA. Modeling Human Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant (2016) 22:1290–8. doi: 10.1016/j.bbmt.2016.04.009

79. Ruggeri L, Capannini N, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. CRISPR-Engineered T Cells in Patients With Refractory Cancer. J Immunol (2013) 190:69.51–1. doi: 10.1073/pdb.bbmt.2012.11.234

80. Somanchi SS, Senyukov VV, Denman CJ, Lee DA. Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells. J Vis Exp (2011) e2540. doi: 10.3791/2540

81. Melsen JE, Threlkeld M, von Osta-Tien DM MM, van Beelen E, Lughart H, Goezen RC, et al. Protocol for Isolation, Stimulation and Functional Profiling of Primary and iPSC-Derived Human NK Cells. Bio Protoc (2020) 10:e3845. doi: 10.11769/BioProtoc.3845

82. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. PloS One (2017) 12:e023064. doi: 10.1371/journal.pone.023064

83. Zhu Y, Huang B, Shi J. Fas Ligand and Lytic Granule Differentially Control Cytotoxic Dynamics of Natural Killer Cell Against Cancer Target. Oncotarget (2016) 7:47163–72. doi: 10.18632/oncotarget.9990

84. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Stadtmauer EA, Fraietta JA, Davis MM, Bredemeyer AJ, Presti RM, French AR, et al. Transplantation for Myeloid Malignancies: A Phase I Trial. Mol Cancer Ther (2002) 295:2097–214. doi: 10.1126/science.aba7365

85. Ruggeri L, Capannini M, Likhit S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, et al. Optimization and Validation of CAR Transduction Into Human Primary NK Cells Using CRISPR and AAV. SSRN Electron J (2021). doi: 10.2139/ssrn.369896

86. Naeimi Kararoudi M, Likhit S, Elmas E, Schwartz M, Sorathia K, Yamamoto K, et al. CD33 Targeting Primary CAR-NK Cells Generated By CRISPR Mediated Gene Insertion Show Enhanced Anti-AML Activity. Blood (2020) 136:2146–27. doi: 10.1182/blood.2020006209

87. Wu SF, Fu T, Jiang YZ, Shao ZM. Natural Killer Cells in Cancer Biology and Therapy. Mol Cancer (2020) 19:120. doi: 10.1186/s12943-020-01238-x

88. Tomchuck S, Leung W, Dallas M. Isolation, Expansion and Function of Cord Blood Natural Killer Cells (P2226). J Immunol (2013) 190:69.51–1. doi: 10.1073/pdb.bbmt.2012.11.234

89. Senyukov VV, Somanchi SS, Shlomchik WD, Tosti A, Perruccio K, Shlomchik WD, et al. Human Haploidentical NK Cells in Patients With Cancer. J Leukoc Biol (2007) 81:305. doi: 10.1111/j.1547-9501.2007.00799.x

90. Madsen AM, Gundersen A, Lydén J, Eikenberry ES, Bredmeyer AP, Lorentzen EM, et al. Anti-Leukemia Activity of Alloreactive NK Cells in KIR Ligand-Mismatched Haploidentical HSCT for Pediatric Patients: Evaluation of the Functional Role of Activating KIR and Inhibition of Inhibitory KIR Specificity. Blood (2009) 113:3119–29. doi: 10.1182/blood-2008-06-161403

91. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Faustch SK, et al. Successful Adoptive Transfer and In Vivo Expansion of Human Haploidentical NK Cells in Patients With Cancer. Blood (2005) 105:3051–7. doi: 10.1182/blood-2004-07-2974

92. Ruggieri L, Capannini M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation. Blood (1999) 94:333–39. doi: 10.1182/blood.V94.33.33431_333_339

93. Shimasaki N, Jain A, Campana D. NK Cells for Cancer Immunotherapy. Nat Rev Drug Discov (2020) 19:200–18. doi: 10.1038/s41573-019-0052-1
106. Aksoy P, Escande C, White TA, Thompson M, Soares S, Benec JC, et al. Regulation of SIRT1 Mediated NAD Dependent Deacetylation: A Novel Role for the Multifunctional Enzyme CD38. Biochem Biophys Res Commun (2006) 349:353–9. doi: 10.1016/j.bbrc.2006.08.066

107. Aksoy P, White TA, Thompson M, Chini EN. Regulation of Intracellular Levels of NAD: A Novel Role for CD38. Biochem Biophys Res Commun (2006) 345:1386–92. doi: 10.1016/j.bbrc.2006.05.042

108. Chiang SH, Harrington WW, Luo G, Milliken NO, Ulrich JC, Chen J, et al. Genetic Ablation of CD38 Protects Against Western Diet-Induced Exercise Intolerance and Metabolic Inflexibility. Plos One (2015) 10:e0134927. doi: 10.1371/journal.pone.0134927

109. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology. Physiol Rev (2008) 88:841–86. doi: 10.1152/physrev.00035.2007

110. Chini EN. CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions. Curr Pharm Des (2009) 15:57–63. doi: 10.2174/13816120978185788

111. Krebs DL, Hilton DJ. SOCS Proteins: Negative Regulators of Cytokine Signaling. Stem Cells (2001) 19:378–87. doi: 10.1634/stemcells.19-5-378

112. Linossi EM, Babon JJ, Hilton DJ, Nicholson SE. Suppression of Cytokine Signaling: The SOCS Perspective. Cytokine Growth Factor Rev (2013) 24:241–8. doi: 10.1016/j.cytogfr.2013.03.005

113. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative Regulation of Cytokine Signaling and Immune Responses by SOCS Proteins. Arthritis Res Ther (2005) 7:100–10. doi: 10.1186/arr1741

114. Hanada T, Kiniyo I, Inagaki-Ohara K, Yoshimura A. Negative Regulation of Cytokine Signaling by CIS/SOCS Family Proteins and Their Roles in Inflammatory Diseases. Rev Phys Biochem Pharmacol (2003) 149:72–86. doi: 10.1007/s10254-003-0015-2

115. Inagaki-Ohara K, Hanada T, Yoshimura A. Negative Regulation of Cytokine Signaling and Inflammatory Diseases. Curr Opin Pharmacol (2003) 3:435–42. doi: 10.1016/S1471-4892(03)00070-5

116. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a Novel Cytokine That Activates Human Natural Killer Cells via Components of the IL-2 Receptor. J Exp Med (1994) 180:1395–403. doi: 10.1084/jem.180.4.1395

117. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, et al. IL-15 Trans-Presentation Promotes Human NK Cell Development and Differentiation In Vivo. J Exp Med (2009) 206:25–34. doi: 10.1084/jem.20082013

118. Geller MA, Miller JS. Use of Allogeneic NK Cells for Cancer Immunotherapy. Immunotherapy (2011) 3:1445–59. doi: 10.2217/iit.11.131

119. Felices M, Lenvik AJ, McElmurry R, Chu S, Hinderlie P, Bendzick L, et al. The PD-1/PD-L1 Axis Modulates the Natural Killer Cell Versus Anti-Tumor Function and Indicates Poor Prognosis in Digestive Cancers. Oncotarget (2016) 7:72961–77. doi: 10.18632/oncotarget.12150

120. Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al. Identification of a Subset of Human Natural Killer Cells Expressing High Levels of Programmed Death 1: A Phenotypic and Functional Characterization. J Allergy Clin Immunol (2017) 139:335–46.e3. doi: 10.1016/j.jaci.2016.04.039

121. Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased Expression of NKG2A on NK Cells Inhibits NK-Cell-Mediated Anti-Tumor Function and Indicates Poor Prognosis in Digestive Cancers. Oncogene (2017) 36:6143–53. doi: 10.1038/onc.2017.209

122. Van der Valk P, Kueppers L, Spaink HP, De Vries BIG, Claessen GJP, van den Berg H, et al. The Role of PD-1/PD-L1 in the Evasion of Tumor-Induced Anergia: A Mechanistic Perspective. J CI99317

123. Arribas J, Esselens C. ADAM17 as a Therapeutic Target in Multiple Diseases. Arthritis Res Ther (2017) 19:68. doi: 10.1186/s13075-017-1391-6

124. Zunke F, Rose-John S. The Shedding Protease ADAM17: Physiology and Pathophysiology. Biochem Biophys Acta Mol Cell Res (2018) 1864:2059–70. doi: 10.1016/j.bbamcr.2017.07.001

125. Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased Expression of Programmed Cell Death Protein 1 on NK Cells Inhibits NK-Cell-Mediated Anti-Tumor Function and Indicates Poor Prognosis in Digestive Cancers. Oncogene (2017) 36:6143–53. doi: 10.1038/onc.2017.209

126. Varri F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, et al. Evasion Via PD-1/PD-L1 on NK Cells and Monocyte/Macrophages is More Prominent in Hodgkin Lymphoma Than DLBCL. Blood (2018) 131:1809–19. doi: 10.1182/blood-2017-07-796342

127. Xiao F, Wolter M, Santos E, Fischer G, Maraninchi D, Busch G, et al. Contribution of PD-1 to Evasion of NK Cells in Tumor Immunotherapy. Cancer Res (2016) 76:5784–93. doi: 10.1158/0008-5472.aacrjune-16-0938

128. Zunke F, Rose-John S. The Shedding Protease ADAM17: Physiology and Pathophysiology. Biochem Biophys Acta Mol Cell Res (2018) 1864:2059–70. doi: 10.1016/j.bbamcr.2017.07.001

129. Wu J, Mishra HK, Walcheck B. Role of ADAM17 as a Regulatory Checkpoint of CD16A in NK Cells and as a Potential Target for Cancer
158. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, et al. GUIDE-Seq Enables Genome-Wide Profiling of Off-Target Cleavage by CRISPR-Cas9 Nucleases. Nat Biotechnol (2015) 33:187–97. doi: 10.1038/nbt.3117

159. Cameron P, Fuller CK, Donohoe PD, Jones BN, Thompson MS, Carter MM, et al. Mapping the Genomic Landscape of CRISPR-Cas9 Cleavage. Nat Methods (2017) 14:600–6. doi: 10.1038/nmeth.4284

160. Lazzarotto CR, Malinini NL, Li Y, Zhang R, Yang Y, Lee G, et al. CHANGE-Seq Reveals Genetic and Epigenetic Effects on CRISPR-Cas9 Genome-Wide Activity. Nat Biotechnol (2020) 38:1317–27. doi: 10.1038/s41587-020-0555-7

161. Bae S, Park J, Kim JS. Cas-OffFinder: A Fast and Versatile Algorithm That Searches for Potential Off-Target Sites of Cas9 RNA-Guided Endonucleases. Bioinformatics (2014) 30:1473–5. doi: 10.1093/bioinformatics/btu048

162. Kelly BJ, Fitch JR, Hu Y, Corsmeir DJ, Zhong H, Wetzell AN, et al. Churchill: An Ultra-Fast, Deterministic, Highly Scalable and Balanced Parallelization Strategy for the Discovery of Human Genetic Variation in Clinical and Population-Scale Genomics. Genome Biol (2015) 16:6. doi: 10.1186/s13059-014-0577-x

163. Zischewski J, Fischer R, Bortesi L. Detection of on-Target and Off-Target Mutations Generated by CRISPR-Cas9 and Other Sequence-Specific Nucleases. Biotechnol Adv (2017) 35:95–104. doi: 10.1016/j.biotechadv.2016.12.003

164. Noble CS, Reddy S, Salas-McKee J, Liu X, June CH, Melenhorst JJ, et al. iGUIDE: An Improved Pipeline for Analyzing CRISPR Cleavage Specificity. Nature Biotechnol (2019) 20:14. doi: 10.1101/30359-019-1625-x

165. Smith C, Gore A, Yan W, Abalde-Aristain L, Li Z, He C, et al. Whole-Genome Sequencing Analysis Reveals High Specificity of CRISPR/Cas9 and TALEN-Based Genome Editing in Human iPS Cells. Cell Stem Cell (2014) 15:12–3. doi: 10.1016/j.stem.2014.06.011

166. Veres A, Gosis BS, Ding Q, Collins R, Ragavendran A, Brand H, et al. Low Incidence of Off-Target Mutations in Individual CRISPR-Cas9 and TALEN Targeted Human Stem Cell Clones Detected by Whole-Genome Sequencing. Cell Stem Cell (2014) 15:27–30. doi: 10.1016/j.stem.2014.04.020

167. Yang L, Grishin D, Wang G, Aach J, Zhang CZ, Chari R, et al. Targeted and Genome-Wide Sequencing Reveal Single Nucleotide Variations Impacting Specificity of Cas9 in Human Stem Cells. Nat Commun (2014) 5:5507. doi: 10.1038/ncomms6507

168. Wu X, Kriz AJ, Sharp PA. Target Specificity of the CRISPR-Cas9 System. Quant Biol (2014) 2:59–70. doi: 10.104184-014-0030-x

169. Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and Feasibility of CRISPR-Edited T Cells in Patients With Refractory non-Small-Cell Lung Cancer. Nat Med (2020) 26:732–40. doi: 10.1038/s41591-020-0840-5

170. Dong MB, Wang G, Chow RD, Ye L, Zhu I, Dui X, et al. Systematic Immunotherapy Target Discovery Using Genome-SCALE In Vivo CRISPR Screens in CDT Cells. Cell (2019) 178:1189–204.e23. doi: 10.1016/j.cell.2019.07.044

171. Wei J, Long L, Zheng W, Dhungana Y, Lim SA, Guy C, et al. Targeting RENAGENE-1 Programs Long-Lived Effector T Cells for Cancer Therapy. Nature (2019) 576:471–6. doi: 10.1038/s41586-019-1821-z

172. Parnas O, Jovanovic M, Eisenhaure TM, Herbst RH, Dixit A, Ye CJ, et al. A Genome-Wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks. Cell (2015) 162:675–86. doi: 10.1016/j.cell.2015.06.059

173. Joung J, Konermann S, Gootenberg JS, Abudayeh OO, Platt RJ, Brigham MD, et al. Genome-Scale CRISPR-Cas9 Knockout and Transcriptional Activation Screening. Nat Protoc (2017) 12:828–63. doi: 10.1038/nprot.2017.016

174. Wang D, Prager BC, Gimple RC, Aguilar B, Alizadeh D, Tang H, et al. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. Cancer Discov (2021) 11:1192–211. doi: 10.1158/2159-8290.CD-20-1243

Conflict of Interest: MN reports personal fees from Kiadis Pharma; in addition, MN has patents US62/825,007; WO2019222503A1; USPTO/103,572; PCT/US2020/02545; US63/018,108; US62/987,524; US62/987,935; self-driving CAR with royalties paid by Kiadis Pharma. DL reports stock from Courier Therapeutics, personal fees and stock options from Cariboo Biosciences, personal fees from Intellia Therapeutics, personal fees from Merck, Sharp, and Dohme, grants, stock, and personal fees from Kiadis Pharma, outside the submitted work; in addition, DL has patents US62/825,007; US63/105,722; US62928,524; PCT-US201/032,670; PCT-US2020/018,384; US62/805,394; US62/987,935; US62/900,245; US62/815,625; PCT-US2020/02545; US62/987,935; self-driving CAR with royalties paid by Kiadis Pharma. DL reports stock from Courier Therapeutics, personal fees and stock options from Cariboo Biosciences, personal fees from Intellia Therapeutics, personal fees from Merck, Sharp, and Dohme, grants, stock, and personal fees from Kiadis Pharma, outside the submitted work; in addition, DL has patents US62/825,007; US63/105,722; US62928,524; PCT-US201/032,670; PCT-US2020/018,384; US62/805,394; US62/987,935; US62/900,245; US62/815,625; Self-driving CAR with royalties paid by Kiadis Pharma and Membership on the NIH Novel and Exception Therapies and Research Advisory Committee (NExTRAC). SM reports stock from Moderna and received licensing fee from Kiadis Pharma.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.